Yüklüyor......
Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine
In 2019, the United States Food and Drug Administration accorded restricted approval to Sanofi Pasteur's Dengvaxia, a live attenuated vaccine (LAV) for dengue fever, a mosquito-borne viral disease, caused by four antigenically distinct dengue virus serotypes (DENV 1-4). The reason for this limi...
Kaydedildi:
| Yayımlandı: | Front Cell Infect Microbiol |
|---|---|
| Asıl Yazarlar: | , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7642463/ https://ncbi.nlm.nih.gov/pubmed/33194810 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fcimb.2020.572681 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|